Ernie Yim, MD
Pulmonary Disease · Honolulu, HINPI 1730238775
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 647 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 36.7% of the total. Among pulmonary disease clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 647 payments — averaging $30.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- GSK$4K
- Insmed, Inc.$2K
- Sanofi$2K
- Amarin Pharma, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$815
- plus $3K from 15 others
What the payments were for
- Food & beverage$19,43399%
- Education$1861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 181 | $7,191 |
| GSK | 176 | $3,820 |
| Insmed, Inc. | 51 | $1,756 |
| Sanofi | 39 | $1,647 |
| Amarin Pharma, Inc. | 74 | $1,399 |
| Regeneron Healthcare Solutions, Inc. | 28 | $815 |
| Novo Nordisk | 26 | $547 |
| Genentech USA, Inc. | 12 | $535 |
| AbbVie | 6 | $416 |
| Lilly USA, LLC | 13 | $410 |
| Amgen(2 entities) | 14 | $390 |
| Boehringer Ingelheim | 14 | $375 |
| Sanofi-aventis U.S. LLC | 2 | $81 |
| Philips North America LLC | 2 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Esperion Therapeutics, Inc. | 2 | $45 |
| Cook Medical LLC | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Novartis | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,618 in reported general payments places this provider in the 90th percentile of 44 pulmonary disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FasenraBenralizumab | 14 | $76,410 |
| NucalaMepolizumab | 12 | $40,831 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $39,296 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $16,037 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,131 |
| Wixela InhubFluticasone Propion/Salmeterol | 35 | $6,540 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $2,891 |
| Rosuvastatin Calcium | 27 | $1,400 |
| Amlodipine Besylate | 71 | $1,212 |
| Atorvastatin Calcium | 50 | $1,093 |
| Montelukast Sodium | 14 | $716 |
| Simvastatin | 14 | $609 |
| Prednisone | 71 | $390 |
| Losartan Potassium | 21 | $384 |
| Pravastatin Sodium | 12 | $323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Symbicort, Breztri Aerosphere | $7,191 | $103,57869 claims |
| GSKNucala, Trelegy Ellipta | $3,820 | $80,12844 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 44 pulmonary disease providers in Hawaii.
Other pulmonary disease in Honolulu
- Takkin LoHonolulu$324K
- Bradley TokeshiHonolulu$41K
- Eric CrawleyHonolulu$17K
- Samuel EvansHonolulu$15K
- Ronson SatoHonolulu$14K
- Alvin FuruikeHonolulu$10K
- James YangHonolulu$8K
- Katsufumi NishidaHonolulu$8K
- Sheri Shimizu-SaitoHonolulu$8K
- Jennifer KayaHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.